Pioneering Psilocybin Treatment Study for Anorexia Shows Promise in Landmark Publication

In a groundbreaking paper published in Psychedelics (Genomic Press), researchers have presented the first clinical trial evaluating psilocybin treatment for anorexia nervosa, marking a significant milestone in eating disorder research. This landmark study, which appears as the cover article in the inaugural issue of this new peer-reviewed journal, has garnered extraordinary global attention, with coverage in over 135 media outlets across multiple languages worldwide.

Global Impact of Research

This paper exemplifies Psychedelics' emerging role as a leading international forum for innovative psychiatric treatment research. Within days of publication, the study's findings were rapidly disseminated across:

• North America: Extensive coverage in English-language media including US News & World Report – see link

• Europe: Coverage in Lithuanian and Polish outlets

• Latin America: Widespread coverage in Spanish-language medical and general news media

• Global reach: Featured in over 150 regional and local news outlets

Study Summary

The research revealed several key findings:

• 60% of participants reported reduced emphasis on physical appearance

• 70% experienced quality-of-life improvements and shifts in personal identity

• 90% ranked their psilocybin dosing session among their top five most meaningful life experiences

• A subset of participants showed clinically significant reductions in eating disorder psychopathology

Research Details

The study appears in Psychedelics alongside an in-depth interview with lead researcher Dr. Stephanie Knatz Peck in the journal's Innovators & Ideas: Rising Star section, providing valuable context about the development and implications of this novel therapeutic approach.

📝 Emerging Topic Review Article: https://doi.org/10.61373/pp024e.0034

Social Media Links:

📄 Rising Star Interview: https://doi.org/10.61373/pp024k.0031

🇺🇸 EurekAlert! Press Release (EN): https://url.genomicpress.com/vxssxt9u

🇪🇸 EurekAlert! Press Release (BR): https://url.genomicpress.com/2p955t87

The research was conducted by Dr. Stephanie Knatz Peck and colleagues at the University of California, San Diego's Eating Disorder Treatment and Research Center, marking the first-ever published clinical trial evaluating a psychedelic drug for eating disorders.

The extraordinary global media response to this publication in Psychedelics demonstrates not only the pressing need for innovative treatments for anorexia nervosa but also establishes the journal as a key platform for communicating critical developments in psychiatric treatment innovation to a global scientific and medical audience.